A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:

NCT00100048

First received: December 22, 2004

Last updated: September 4, 2015

Last verified: September 2015

History of Changes

Results First Received: January 21, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
Conditions:	HIV Infections Acquired Immunodeficiency Syndrome
Interventions:	Drug: Comparator: MK0518 monotherapy Drug: Comparator: MK0518 combination therapy Drug: Comparator: efavirenz Drug: Comparator: tenofovir Drug: Comparator: lamivudine Drug: Placebo monotherapy

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Primary therapy period: For Part I (10 day monotherapy): 24-Jan-2005 to 04-May-2005 Part II (Dose Ranging): 14-Jun-2005 to 04-Oct-2006 (48 weeks); 14-Jun-2005 to 12-Jul-2010 (240 weeks) Multicenter (29) in the United States (14) and Ex-US (15)

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Primary therapy period:

For Part I (10 day monotherapy): 24-Jan-2005 to 04-May-2005

Part II (Dose Ranging): 14-Jun-2005 to 04-Oct-2006 (48 weeks); 14-Jun-2005 to 12-Jul-2010 (240 weeks)

Multicenter (29) in the United States (14) and Ex-US (15)

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Patients with Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) of at least 5000 copies/mL and cluster of differentiation 4 (CD4) cell counts of at least 100 cells/mm3. All patients must have met laboratory criteria. 206 enrolled; 5 from Cohort I did not continue to the combination phase. Therefore 201 entered the combination phase.

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Patients with Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) of at least 5000 copies/mL and cluster of differentiation 4 (CD4) cell counts of at least 100 cells/mm3. All patients must have met laboratory criteria.

206 enrolled; 5 from Cohort I did not continue to the combination phase. Therefore 201 entered the combination phase.

Reporting Groups

	Description
MK0518 100 mg b.i.d.	Cohort I-Monotherapy Phase MK0518 100 mg twice daily (b.i.d.) Cohort II Combined-Combination Therapy Phase MK0518 100 mg + tenofovir + lamivudine
MK0518 200 mg b.i.d	Cohort I-Monotherapy Phase MK0518 200 mg b.i.d Cohort II Combined-Combination Therapy Phase MK0518 200 mg + tenofovir + lamivudine
MK0518 400 mg b.i.d.	Cohort I-Monotherapy Phase MK0518 400 mg b.i.d. Cohort II Combined-Combination Therapy Phase MK0518 400 mg + tenofovir + lamivudine
MK0518 600 mg b.i.d.	Cohort I-Monotherapy Phase MK0518 600 mg b.i.d. Cohort II Combined-Combination Therapy Phase MK0518 600 mg + tenofovir + lamivudine
Placebo	Cohort I-Monotherapy Phase Placebo to MK0518 b.i.d.
Efavirenz 600 mg q.h.s.	Cohort II Combined-Combination Therapy Phase efavirenz 600 mg every night at bedtime (q.h.s.)

Participant Flow for 2 periods

Period 1: Cohort I-Monotherapy Phase 10 Days

	MK0518 100 mg b.i.d.	MK0518 200 mg b.i.d	MK0518 400 mg b.i.d.	MK0518 600 mg b.i.d.	Placebo	Efavirenz 600 mg q.h.s.
STARTED	7	7	6	8	7	0 ^[1]
Treated	7	7	6	8	7	0
COMPLETED	7 ^[2]	7 ^[2]	6 ^[3]	8 ^[3]	7 ^[4]	0
NOT COMPLETED	0	0	0	0	0	0

^[1]	participants only assigned Efavirenz 600 mg q.h.s in Cohort II Combined-Combination Therapy Phase
^[2]	7 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)
^[3]	6 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)
^[4]	4 Subjects Continued to Cohort II, as part of the Efavirenz 600 mg q.d. arm

Period 2: Cohort I & II-Combination Therapy Phase

	MK0518 100 mg b.i.d.	MK0518 200 mg b.i.d	MK0518 400 mg b.i.d.	MK0518 600 mg b.i.d.	Placebo	Efavirenz 600 mg q.h.s.
STARTED	41 ^[1]	40 ^[2]	41 ^[3]	40 ^[4]	0 ^[5]	39 ^[6]
Treated	39	40	41	40	0	38
Never Treated	2 ^[7]	0	0	0	0	1 ^[7]
COMPLETED	27	31	28	30	0	26
NOT COMPLETED	14	9	13	10	0	13
Never Treated	2	0	0	0	0	1
Adverse Event	0	1	2	0	0	1
Lack of Efficacy	1	3	0	0	0	2
Lost to Follow-up	2	1	3	2	0	3
Withdrawal by Subject	1	2	2	5	0	4
Other Reason	7	1	4	2	0	0
Completed Base Study, Did Not Continue	1	1	2	0	0	2
Laboratory Adverse Experience	0	0	0	1	0	0

^[1]	7 subjects from the Monotherapy Phase and 34 new subjects
^[2]	7 subjects from the Monotherapy Phase and 33 new subjects
^[3]	6 subjects from the Monotherapy Phase and 35 new subjects
^[4]	8 subjects from the Monotherapy Phase and 32 new subjects
^[5]	participants only assigned Placebo in Cohort I-Monotherapy Phase.
^[6]	4 subjects from the Monotherapy Phase (Placebo)and 35 new subjects
^[7]	Randomised in Cohort II did not start Period

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
MK0518 100 mg b.i.d.	Cohort I-Monotherapy Phase (10 Days) MK0518 100 mg twice daily (b.i.d.) Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100 mg b.i.d
MK0518 200 mg b.i.d	Cohort I-Monotherapy Phase (10 Days) MK0518 200 mg b.i.d Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 200 mg + tenofovir + lamivudine
MK0518 400 mg b.i.d.	Cohort I-Monotherapy Phase (10 Days) MK0518 400 mg b.i.d. Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 400 mg + tenofovir + lamivudine
MK0518 600 mg b.i.d.	Cohort I-Monotherapy Phase (10 Days) MK0518 600 mg b.i.d. Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 600 mg + tenofovir + lamivudine
Placebo / Efavirenz 600 mg Once Daily (q.d.)	Cohort I-Monotherapy Phase (10 Days) Placebo to MK0518 b.i.d. Cohort II Combined-Combination Therapy Phase (48 Weeks) Efavirenz + Tenofovir + Lamivudine
Total	Total of all reporting groups

Baseline Measures

MK0518 100 mg b.i.d.

MK0518 200 mg b.i.d

MK0518 400 mg b.i.d.

MK0518 600 mg b.i.d.

Placebo / Efavirenz 600 mg Once Daily (q.d.)

Total

Overall Participants Analyzed
[Units: Participants]

206

Age ^[1]
[Units: Years]
Mean (Full Range)

Cohort I

46
(31 to 68)

37
(22 to 57)

41
(25 to 55)

39
(30 to 49)

36
(21 to 51)

40
(21 to 68)

Cohort II

34
(19 to 58)

31
(21 to 56)

34
(19 to 50)

36
(20 to 49)

36
(22 to 54)

35
(19 to 58)

Cohort I & II Combined

37
(19 to 68)

34
(21 to 57)

36
(19 to 55)

37
(20 to 49)

36
(22 to 54)

36
(19 to 68)

^[1]

Cohort I Participants: MK0518 100 mg b.i.d. (7); MK0518 200 mg b.i.d. (7); MK0518 400 mg b.i.d. (6); MK0518 600 mg b.i.d. (8); Placebo Cohort (7)

Cohort II Participants: MK0518 100 mg b.i.d. (33); MK0518 200 mg b.i.d. (33); MK0518 400 mg b.i.d. (35); MK0518 600 mg b.i.d. (34); Efavirenz 600 mg q.d. (34)

Cohort I & II Participants Combined: MK0518 100 mg b.i.d. (39); MK0518 200 mg b.i.d. (40); MK0518 400 mg b.i.d. (41); MK0518 600 mg b.i.d. (40); Efavirenz 600 mg q.d. (38)

Gender, Customized
[Units: Participants]

Female (Cohort I)

Male (Cohort I)

Female (Cohort II)

Male (Cohort II)

130

Never Treated Cohort II

Race/Ethnicity, Customized
[Units: Participants]

White (Cohort I)

Black (Cohort I)

Asian (Cohort I)

Hispanic (Cohort I)

White (Cohort II)

Black (Cohort II)

Asian (Cohort II)

Hispanic (Cohort II)

Other (Cohort II)

Never Treated (Cohort II)

Cluster of differentiation 4 (CD4) Cell Count ^[1]
[Units: Cells/mm^3]
Mean (Full Range)

Cohort I

415
(138 to 745)

343
(149 to 624)

256
(96 to 602)

569
(241 to 1034)

343
(115 to 599)

394
(96 to 1034)

Cohort II

293
(76 to 736)

292
(70 to 723)

348
(95 to 1017)

245
(99 to 734)

276
(77 to 744)

291
(70 to 1017)

Cohort I and II Combined

272
(76 to 758)

277
(70 to 723)

293
(95 to 1017)

244
(99 to 786)

225
(77 to 744)

266
(70 to 1017)

^[1]

Cohort I Participants: MK0518 100 mg b.i.d. (7); MK0518 200 mg b.i.d. (7); MK0518 400 mg b.i.d. (6); MK0518 600 mg b.i.d. (8); Placebo Cohort (7) Cohort II Participants: MK0518 100 mg b.i.d. (33); MK0518 200 mg b.i.d. (33); MK0518 400 mg b.i.d. (35); MK0518 600 mg b.i.d. (34); Efavirenz 600 mg q.d. (34) Cohort I & II Participants Combined: MK0518 100 mg b.i.d. (39); MK0518 200 mg b.i.d. (40); MK0518 400 mg b.i.d. (41); MK0518 600 mg b.i.d. (40); Efavirenz 600 mg q.d. (38)

Plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) ^[1]
[Units: copies/mL]
Geometric Mean (Full Range)

Cohort I

44989
(3890 to 225000)

34143
(5420 to 168000)

37728
(6850 to 152000)

93911
(17100 to 388000)

58412
(7630 to 456000)

51496
(3890 to 456000)

Cohort II

65982
(4200 to 750000)

73646
(7490 to 750000)

47019
(2440 to 499000)

61929
(3450 to 750000)

76752
(7500 to 675000)

63965
(2440 to 750000)

Cohort I and II Combined

58206
(4200 to 750000)

64715
(7490 to 750000)

43083
(2440 to 499000)

57919
(3450 to 750000)

67554
(3340 to 675000)

57437
(2440 to 750000)

^[1]

Outcome Measures

Show All Outcome Measures

1. Primary:

Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I) [ Time Frame: Baseline and Day 10 ]

Show Outcome Measure 1

2. Primary:

Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I) [ Time Frame: 10 days ]

Show Outcome Measure 2

3. Primary:

Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II) [ Time Frame: Week 24 ]

Show Outcome Measure 3

4. Primary:

Number of Patients With Clinical Adverse Experiences (CAEs) [ Time Frame: 48 weeks ]

Show Outcome Measure 4

5. Primary:

Number of Patients With Serious CAEs (Cohort I and II Combined) [ Time Frame: 48 weeks ]

Show Outcome Measure 5

6. Primary:

Number of Patients With Serious CAEs and Non-serious CAEs at Week 144 [ Time Frame: 144 Weeks ]

Show Outcome Measure 6

7. Primary:

Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs) [ Time Frame: Week 240 ]

Show Outcome Measure 7

8. Primary:

Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240 [ Time Frame: Week 240 ]

Show Outcome Measure 8

9. Secondary:

Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II) [ Time Frame: Week 24 ]

Hide Outcome Measure 9

Measure Type	Secondary
Measure Title	Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)
Measure Description	No text entered.
Time Frame	Week 24

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.

Reporting Groups

	Description
MK0518 100 mg b.i.d.	Cohort II Combined-Combination Therapy Phase MK0518 100 mg + tenofovir + lamivudine
MK0518 200 mg b.i.d	Cohort II Combined-Combination Therapy Phase MK0518 200 mg + tenofovir + lamivudine
MK0518 400 mg b.i.d.	Cohort II Combined-Combination Therapy Phase MK0518 400 mg + tenofovir + lamivudine
MK0518 600 mg b.i.d.	Cohort II Combined-Combination Therapy Phase MK0518 600 mg + tenofovir + lamivudine
EFV Combo Therapy	EFV Combo Therapy Phase - Cohort II efavirenz + tenofovir + lamivudine

Measured Values

	MK0518 100 mg b.i.d.	MK0518 200 mg b.i.d	MK0518 400 mg b.i.d.	MK0518 600 mg b.i.d.	EFV Combo Therapy
Participants Analyzed [Units: Participants]	33	33	35	34	34
Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II) [Units: Participants]	28	27	33	32	31

No statistical analysis provided for Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)

10. Secondary:

Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II) [ Time Frame: Baseline and Week 24 ]

Show Outcome Measure 10

11. Secondary:

Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II) [ Time Frame: Baseline and Week 24 ]

Show Outcome Measure 11

12. Secondary:

Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 12

13. Secondary:

Change From Baseline in Plasma HIV RNA at Week 96 [ Time Frame: Baseline and Week 96 ]

Show Outcome Measure 13

14. Secondary:

Change From Baseline in CD4 Cell Count at Week 96 [ Time Frame: Baseline and Week 96 ]

Show Outcome Measure 14

15. Secondary:

Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240 [ Time Frame: Week 240 ]

Show Outcome Measure 15

16. Secondary:

Change From Baseline in Plasma HIV RNA at Week 240 [ Time Frame: Baseline and Week 240 ]

Show Outcome Measure 16

17. Secondary:

Change From Baseline in CD4 (T-helper) Cell Count at Week 240 [ Time Frame: Baseline and Week 240 ]

Show Outcome Measure 17

18. Other Pre-specified:

Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48 [ Time Frame: 48 weeks ]

Show Outcome Measure 18

19. Other Pre-specified:

Number of Patients With Drug-related CAEs [ Time Frame: 48 weeks ]

Show Outcome Measure 19

20. Other Pre-specified:

Number of Patients With Serious Drug-related CAEs [ Time Frame: 48 Weeks ]

Show Outcome Measure 20

21. Other Pre-specified:

Number of Patients That Discontinued With CAEs [ Time Frame: 48 Weeks ]

Show Outcome Measure 21

22. Other Pre-specified:

Number of Patients With Laboratory Adverse Experiences (LAEs) [ Time Frame: 48 Weeks ]

Show Outcome Measure 22

23. Other Pre-specified:

Number of Patients With Serious LAEs [ Time Frame: 48 Weeks ]

Show Outcome Measure 23

24. Other Pre-specified:

Number of Patients With Drug-related LAEs [ Time Frame: 48 Weeks ]

Show Outcome Measure 24

25. Other Pre-specified:

Number of Patients With Serious Drug-related LAEs [ Time Frame: 48 Weeks ]

Show Outcome Measure 25

26. Other Pre-specified:

Number of Patients That Discontinued With LAEs [ Time Frame: 48 Weeks ]

Show Outcome Measure 26

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Show More Information

To Top